AllianceBernstein’s Iovance Biotherapeutics IOVA Stock Holding History

AllianceBernstein’s Portfolio IOVA Stock Details IOVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.48M	Buy	421,040 +99,390	+31%	+$378K	﹤0.01%	2197
2026 Q1	$878K	Buy	321,650 +62,760	+24%	+$201K	﹤0.01%	2384
2025 Q4	$707K	Hold	258,890	–	–	﹤0.01%	2488
2025 Q3	$562K	Hold	258,890	–	–	﹤0.01%	2619
2025 Q2	$445K	Sell	258,890 -4,600	-2%	-$11.4K	﹤0.01%	2714
2025 Q1	$877K	Sell	263,490 -501,909	-66%	-$2.59M	﹤0.01%	2308
2024 Q4	$5.66M	Buy	765,399 +134,269	+21%	+$1.24M	﹤0.01%	1433
2024 Q3	$5.93M	Buy	631,130 +301,098	+91%	+$2.85M	﹤0.01%	1447
2024 Q2	$2.65M	Buy	330,032 +14,592	+5%	+$156K	﹤0.01%	1795
2024 Q1	$4.67M	Buy	315,440 +62,550	+25%	+$728K	﹤0.01%	1489
2023 Q4	$2.06M	Sell	252,890 -90,300	-26%	-$472K	﹤0.01%	1919
2023 Q3	$1.56M	Sell	343,190 -528,913	-61%	-$3.45M	﹤0.01%	2009
2023 Q2	$6.14M	Sell	872,103 -78,929	-8%	-$565K	﹤0.01%	1354
2023 Q1	$5.81M	Buy	951,032 +617,131	+185%	+$4.26M	﹤0.01%	1339
2022 Q4	$2.13M	Buy	333,901 +162,401	+95%	+$1.27M	﹤0.01%	1877
2022 Q3	$1.64M	Hold	171,500	–	–	﹤0.01%	2009
2022 Q2	$1.89M	Buy	171,500 +106,340	+163%	+$1.39M	﹤0.01%	1987
2022 Q1	$1.08M	Sell	65,160 -188,547	-74%	-$2.92M	﹤0.01%	2402
2021 Q4	$4.84M	Buy	253,707 +17,665	+7%	+$389K	﹤0.01%	1640
2021 Q3	$5.82M	Buy	236,042 +127,366	+117%	+$3M	﹤0.01%	1526
2021 Q2	$2.83M	Sell	108,676 -2,267,138	-95%	-$58.9M	﹤0.01%	1969
2021 Q1	$75.2M	Buy	2,375,814 +589,285	+33%	+$24.4M	0.03%	488
2020 Q4	$82.9M	Buy	1,786,529 +573,719	+47%	+$22.8M	0.04%	432
2020 Q3	$39.9M	Sell	1,212,810 -159,819	-12%	-$4.9M	0.02%	604
2020 Q2	$37.7M	Sell	1,372,629 -60,763	-4%	-$2M	0.02%	599
2020 Q1	$42.9M	Sell	1,433,392 -438,444	-23%	-$11.6M	0.03%	495
2019 Q4	$51.8M	Buy	1,871,836 +80,699	+5%	+$1.84M	0.03%	531
2019 Q3	$32.6M	Buy	1,791,137 +653,618	+57%	+$14.5M	0.02%	643
2019 Q2	$27.9M	Buy	1,137,519 +912,419	+405%	+$13.7M	0.02%	691
2019 Q1	$2.14M	Buy	225,100 +75,000	+50%	+$728K	﹤0.01%	1851
2018 Q4	$1.33M	Buy	150,100 +4,700	+3%	+$45.3K	﹤0.01%	2058
2018 Q3	$1.64M	Hold	145,400	–	–	﹤0.01%	2078
2018 Q2	$1.86M	Sell	145,400 -70,700	-33%	-$1.03M	﹤0.01%	1977
2018 Q1	$3.65M	Buy	216,100 +154,500	+251%	+$2.34M	﹤0.01%	1396
2017 Q4	$493K	Hold	61,600	–	–	﹤0.01%	2529
2017 Q3	$477K	Hold	61,600	–	–	﹤0.01%	2588
2017 Q2	$453K	Buy	61,600 +22,000	+56%	+$140K	﹤0.01%	2649
2017 Q1	$295K	Hold	39,600	–	–	﹤0.01%	2719
2016 Q4	$275K	Hold	39,600	–	–	﹤0.01%	2778
2016 Q3	$326K	Hold	39,600	–	–	﹤0.01%	2674
2016 Q2	$321K	Buy	39,600 +28,400	+254%	+$178K	﹤0.01%	2660
2016 Q1	$57K	Hold	11,200	–	–	﹤0.01%	2870
2015 Q4	$86K	Buy	+11,200	New	+$77.7K	﹤0.01%	2861

Other funds holding IOVA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

MFM

MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

AllianceBernstein's IOVA Position: Q2 2026 in Review

AllianceBernstein increased its Iovance Biotherapeutics (IOVA) stake by 31% in Q2 2026, buying an estimated $378K and bringing the position to 421,040 shares worth $1.48M. The position accounts for ﹤0.01% of the portfolio, ranked #2197.

AllianceBernstein first reported a position in IOVA in Q4 2015 and has held it in 43 quarters since. The position peaked at $82.9M in Q4 2020. 292 funds tracked by Wall St. Rank hold IOVA as of Q2 2026.

AllianceBernstein held 421,040 shares of Iovance Biotherapeutics worth $1.48M as of Q2 2026.
AllianceBernstein bought 99,390 Iovance Biotherapeutics shares in Q2 2026, an estimated $378K.
Iovance Biotherapeutics made up ﹤0.01% of AllianceBernstein's portfolio in Q2 2026, its #2197 holding.
AllianceBernstein first reported a position in Iovance Biotherapeutics in Q4 2015 and has held it in 43 quarters since.
AllianceBernstein's Iovance Biotherapeutics position peaked at $82.9M in Q4 2020.
292 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2026.

Based on AllianceBernstein's 13F filing for Q2 2026, filed 14 Aug 2026.